Ko; Eunhwa

Patent Applications and Registrations

Patent applications and USPTO patent grants for Ko; Eunhwa.The latest application filed is for "pyrrolopyrimidine inhibitors of wild-type and mutant forms of lrrk2".

Company Profile

7.6.13

Ko; Eunhwa - Daegu KR
Ko; Eunhwa - Incheon KR
KO; Eunhwa - Dong-gu KR
Ko; Eunhwa - New Haven CT

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Compound exhibiting enteropeptidase inhibitory activity Grant 11,447,480 - Kim , et al. September 20, 2	2022-09-20
Pyrrolopyrimidine Inhibitors Of Wild-type And Mutant Forms Of Lrrk2 App 20220204515 - Gray; Nathanael S. ; et al.	2022-06-30
Pyrrolo-pyridine Derivative Compound, Method For Preparing Same, And Pharmaceutical Composition Containing Same As Active Ingredient For Prevention Or Treatment Of Protein Kinase-related Diseases App 20220106307 - CHOI; Hwan Geun ; et al.	2022-04-07
Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease Grant 11,208,412 - Choi , et al. December 28, 2	2021-12-28
Azaindole Inhibitors Of Wild-type And Mutant Forms Of Lrrk2 App 20210347772 - Gray; Nathanael S. ; et al.	2021-11-11
Novel Compound Exhibiting Enteropeptidase Inhibitory Activity App 20210284634 - KIM; Young Kwan ; et al.	2021-09-16
Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases Grant 11,117,892 - Choi , et al. September 14, 2	2021-09-14
Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer App 20210267997 - Choi; Hwan Geun ; et al.	2021-09-02
Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer Grant 10,870,647 - Choi , et al. December 22, 2	2020-12-22
Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same App 20200325130 - CREWS; Craig ; et al.	2020-10-15
Pyrrolo-pyrimidine Derivative Compound, Preparation Method Therefor, And Pharmaceutical Composition Comprising Same Compound As App 20200239474 - CHOI; Hwan Geun ; et al.	2020-07-30
Pyrrolo-pyridine Derivative Compound, Method For Preparing Same, And Pharmaceutical Composition Containing Same As Active Ingred App 20200207756 - CHOI; Hwan Geun ; et al.	2020-07-02
Novel Imidazopyridine Derivative, Method For Preparing Same, And Pharmaceutical Composition Containing Same As Active Ingredient App 20190315738 - Choi; Hwan Geun ; et al.	2019-10-17
Bifunctional Compounds For Her3 Degradation And Methods Of Use App 20190016703 - GRAY; Nathanael S. ; et al.	2019-01-17
Estrogen-related receptor alpha based protac compounds and associated methods of use Grant 10,071,164 - Crew , et al. September 11, 2	2018-09-11
Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same App 20180186785 - CREWS; Craig ; et al.	2018-07-05
Proteolysis targeting chimera compounds and methods of preparing and using same Grant 9,938,264 - Crews , et al. April 10, 2	2018-04-10
Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same App 20170121321 - CREWS; Craig ; et al.	2017-05-04
Estrogen-related Receptor Alpha Based Protac Compounds And Associated Methods Of Use App 20160045607 - Crew; Andrew ; et al.	2016-02-18

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.